ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma

Backgrounds & purpose: Prognosis of patients with primary central nervous system lymphoma (PCNSL) remains poor despite multiagent immunochemotherapy, and standard of care for relapsed or refractory (r/r) PCNSL has not been established. Recent progresses on molecular genetics and biology of PCNSL...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurooncol Adv
Auteurs principaux: Kobayashi, Keiichi, Sasaki, Nobuyoshi, Saito, Kuniaki, Yamagishi, Yuki, Matsumoto, Yoshie, Sasaki, Yuta, Shimizu, Saki, Shiokawa, Yoshiaki, Nagane, Motoo
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Supplement Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699110/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.078
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires